hVIVO – a company focused on testing global infectious and respiratory disease products through clinical trials – has recorded positive interim results from its study involving Cidara Therapeutics’ CD388 influenza therapy.
hVIVO is currently conducting the wider phase 2a single-location, randomised, placebo-controlled trial using its established ‘H3N2 Influenza Human Challenge Study Model’.
Candidate CD388 is a long-acting conjugate antiviral for treating seasonal influenza. The mid-term analysis comes from research on 56 healthy volunteers, with 28 receiving a single dose of CD388 –150mg – and the remaining members of the group receiving a placebo. The entire cohort also received H3N2 influenza – a notable challenge agent.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
